2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer
Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.
Related Articles
Asciminib for Ph+ ALL: a step forward?
In this issue of Blood, Luskin et al present results of the first phase 1 trial combining asciminib, an allosteric BCR::ABL1 inhibitor, with the tyrosine k
Sallman on Eprenetapopt and Azacitidine in TP53-Mutant MDS/AML
David Sallman, MD, discusses using eprenetapopt and azacitidine in TP53-mutant myelodysplastic syndrome and acute myeloid leukemia post-allogeneic stem cell transplantation.
Protocol Reduces Side Effects Before Myeloma Transplant : Oncology Times
An abstract is unavailable.
Lete-Cel Generates Durable Responses in Synovial Sarcoma and Myoxid/Round Cell Liposarcoma
Patients with metastatic myxoid/round cell liposarcoma or synovial sarcoma expressing NY-ESO-1 and HLA achieved an ORR of 42% with lete-cel.
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
Ma et al. identify P4HA1 as a critical regulator of CD8+ T cell activity in solid tumor microenvironment. P4HA1 induction in CD8+ T cells causes mitochondrial dysfunction and…
AI accurately identifies targetable alterations in lung cancer histological images
Nature Reviews Clinical Oncology – DeepGEM, an artificial intelligence (AI)-based model, accurately predicts the presence of key genomic alterations in histological slides prepared from samples…
APP Lifetime Achievement Award – Tandem Meetings News
This year’s recipient of the APP Lifetime Achievement Award, Sameeya Ahmed-Winston, CPNP, CPHON, BMTCN, shares insights and her outlook on being an advanced practice provider…
Dry January is over. Now what? Preventing 7 types of cancer by cutting alcohol: HealthLink
A Fred Hutch cancer epidemiologist highlights alcohol’s cancer link during Cancer Prevention Month.
World Cancer Day Shines Light on Therapeutic Advancements in Cancer Care
Dr. John Oertle discussed the significance of World Cancer Day, raising awareness about cancer care advancements and improving patient outcomes.
Dr Moore on the 2024 FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer
Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.